Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients with no prior antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient’s current dose of metformin or the nearest appropriate therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is required in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Improvement of glycemic control in adults with type 2 diabetes mellitus
Difficulty in controlling blood sugar in type 2 diabetes
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication contains dapagliflozin and metformin and is primarily used to control blood sugar in adult patients with type 2 diabetes. It is administered as an adjunctive treatment for patients who are on dietary and exercise regimens to enhance blood glucose control. In particular, for patients with type 2 diabetes who do not achieve adequate blood glucose control and have cardiovascular diseases or risk factors, it is important to refer to expert guidelines regarding the cardiovascular effects of dapagliflozin. This medication helps in safely controlling blood glucose and is effectively used in overall diabetes management.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients with no prior antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient’s current dose of metformin or the nearest appropriate therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is required in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Precautions
This medication helps in controlling blood sugar.
However, there are several important precautions to be taken when using this medication.
First, this medication can rarely cause a dangerous condition called lactic acidosis. Lactic acidosis occurs when there is a build-up of lactic acid in the body, which can be life-threatening if severe, so consult a doctor immediately if symptoms appear.
Additionally, when this medication is used with insulin or other diabetes medications, hypoglycemia may occur, so blood glucose levels should be closely monitored, and medication dosages adjusted if necessary.
This medication should not be administered to patients with severely impaired kidney function, patients in a dehydrated state, patients with serious infections or heart issues, and those with acute myocardial infarction.
Also, pregnant or breastfeeding women, as well as individuals with certain genetic disorders, should not take this medication.
Before administration, fluid status and kidney function must be evaluated, and special caution is necessary for the elderly or individuals with slightly impaired kidney function.
This medication can increase urination, possibly leading to decreased fluid levels or low blood pressure, so those at risk for hypotension should frequently check their blood pressure and fluid status.
During treatment, genital and urinary infections may occur, and if these symptoms appear, immediate treatment is required.
Furthermore, this medication can lower vitamin B12 levels, so it is advisable to check vitamin B12 status during long-term use.
Alcohol consumption may increase the risk of side effects from this medication, so excessive drinking should be avoided while on this drug.
If undergoing surgery or iodine contrast tests, administration should be temporarily halted, and it should be restarted only after confirming normal kidney function.
In case of overdose, appropriate treatment is required, and while this medication does not significantly affect driving or machine operation abilities, dizziness may occur, so caution is advised.
Finally, this medication should be kept out of reach of children and stored in its original container to maintain its quality.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
fluid volume depletion
thirst
Show 85 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
elevated hematocrit
decreased renal creatinine clearance
dyslipidemia
elevated serum creatinine
elevated blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
chest pain
thermal burns
wrist fractures
gastrointestinal stromal tumors
malignant neoplasm of the lung
uterine fibroids
atrial fibrillation
acute cholecystitis
epigastric pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland masses
toothache
headache
facial paralysis
peripheral neuropathy
sensory abnormalities
drowsiness
tremors
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
elevated alanine aminotransferase
increased blood glucose
tendinitis
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
periarticular inflammation
tenosynovitis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
skin abrasion
pruritus
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is advisable to keep the storage temperature between 1°C and 30°C at room temperature. This will help maintain the medication's effectiveness and safety over time.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.